Vontobel Holding Ltd. Sells 8,300 Shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN)

Vontobel Holding Ltd. lowered its stake in shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) by 34.9% during the fourth quarter, HoldingsChannel reports. The firm owned 15,500 shares of the company’s stock after selling 8,300 shares during the quarter. Vontobel Holding Ltd.’s holdings in Day One Biopharmaceuticals were worth $226,000 as of its most recent SEC filing.

Several other large investors also recently made changes to their positions in the stock. China Universal Asset Management Co. Ltd. grew its holdings in Day One Biopharmaceuticals by 130.9% during the third quarter. China Universal Asset Management Co. Ltd. now owns 2,226 shares of the company’s stock worth $27,000 after purchasing an additional 1,262 shares during the period. Amalgamated Bank lifted its position in shares of Day One Biopharmaceuticals by 35.7% in the third quarter. Amalgamated Bank now owns 8,628 shares of the company’s stock valued at $106,000 after buying an additional 2,268 shares during the last quarter. Exchange Traded Concepts LLC boosted its stake in shares of Day One Biopharmaceuticals by 34.0% during the 4th quarter. Exchange Traded Concepts LLC now owns 10,072 shares of the company’s stock worth $147,000 after acquiring an additional 2,554 shares during the period. Arizona State Retirement System increased its holdings in shares of Day One Biopharmaceuticals by 8.8% during the 3rd quarter. Arizona State Retirement System now owns 12,363 shares of the company’s stock worth $152,000 after acquiring an additional 995 shares during the last quarter. Finally, Principal Financial Group Inc. raised its stake in Day One Biopharmaceuticals by 9.7% in the 3rd quarter. Principal Financial Group Inc. now owns 17,781 shares of the company’s stock valued at $218,000 after acquiring an additional 1,569 shares during the period. Institutional investors and hedge funds own 87.95% of the company’s stock.

Wall Street Analyst Weigh In

DAWN has been the subject of a number of research analyst reports. JPMorgan Chase & Co. lifted their price objective on shares of Day One Biopharmaceuticals from $32.00 to $36.00 and gave the stock an “overweight” rating in a research report on Monday. Piper Sandler reiterated an “overweight” rating and issued a $40.00 price target on shares of Day One Biopharmaceuticals in a research note on Tuesday, March 26th. Oppenheimer restated a “market perform” rating on shares of Day One Biopharmaceuticals in a research report on Tuesday, February 27th. Needham & Company LLC lifted their target price on Day One Biopharmaceuticals from $30.00 to $33.00 and gave the stock a “buy” rating in a report on Wednesday. Finally, The Goldman Sachs Group reduced their target price on shares of Day One Biopharmaceuticals from $50.00 to $44.00 and set a “buy” rating for the company in a research report on Tuesday, February 27th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and six have issued a buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $39.33.

Day One Biopharmaceuticals Price Performance

Shares of NASDAQ DAWN opened at $15.19 on Thursday. The business has a fifty day moving average price of $15.28 and a two-hundred day moving average price of $13.79. The stock has a market capitalization of $1.33 billion, a PE ratio of -6.38 and a beta of -1.48. Day One Biopharmaceuticals, Inc. has a fifty-two week low of $9.67 and a fifty-two week high of $17.85.

Day One Biopharmaceuticals (NASDAQ:DAWN) last announced its quarterly earnings data on Monday, February 26th. The company reported ($0.64) EPS for the quarter, missing the consensus estimate of ($0.57) by ($0.07). On average, equities analysts expect that Day One Biopharmaceuticals, Inc. will post -2.66 EPS for the current year.

Insider Activity at Day One Biopharmaceuticals

In other news, insider Samuel C. Blackman sold 20,000 shares of the stock in a transaction dated Tuesday, February 27th. The shares were sold at an average price of $16.11, for a total value of $322,200.00. Following the completion of the transaction, the insider now owns 1,224,662 shares of the company’s stock, valued at $19,729,304.82. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. In related news, CEO Jeremy Bender sold 7,615 shares of Day One Biopharmaceuticals stock in a transaction that occurred on Friday, February 16th. The shares were sold at an average price of $15.25, for a total transaction of $116,128.75. Following the sale, the chief executive officer now directly owns 721,813 shares in the company, valued at approximately $11,007,648.25. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Samuel C. Blackman sold 20,000 shares of the business’s stock in a transaction that occurred on Tuesday, February 27th. The stock was sold at an average price of $16.11, for a total transaction of $322,200.00. Following the sale, the insider now directly owns 1,224,662 shares in the company, valued at $19,729,304.82. The disclosure for this sale can be found here. Insiders have sold 55,781 shares of company stock valued at $883,160 over the last ninety days. 8.40% of the stock is owned by corporate insiders.

About Day One Biopharmaceuticals

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.